Ma Xiao, Tang Cheng-Wei, Huang Zhi-Yin, Zhang Ming-Guang, Liu Fang, Wang Chun-Hui, Wang Rui, Tong Huan, Liu Ling
Department of Gastroenterology,West China Hospital,Sichuan University,Chengdu 610041,China.
Sichuan Da Xue Xue Bao Yi Xue Ban. 2017 Nov;48(6):933-936.
To evaluate the effect of proton pump inhibitors (PPIs) therapy on severe acute pancreatitis (SAP) patients.
Forty five patients with SAP recruited in our center from October 2015 to October 2016,were randomly assigned into two groups: convention group (C group,=21) and convention+esomeprazole group (C+E group,=24). C+E group received esomeprazole 40 mg/d intravenously for 1 week,whereas C group only received baseline treatment. Serum C-reactive protein (CRP),interleukin-6 (IL-6) and interleukin-8 (IL-8),tumor necrosis factor-α (TNF-α) and procalcitonin (PCT) were detected by ELISA on the first day (baseline) and the seventh day. Acute physiology and chronic health evaluation Ⅱ scores (APACHE Ⅱ),systemic inflammatory response syndrome scores (SIRS) and modified Marshall scoring system (Marshall) were obtained at 1 d (baseline),3 d and 7 d. Upper gastrointestinal manifestation (peptic ulcer) and gastric pH were detected by endoscopic examination at 7 d. Fecal occult blood test was performed at 7 d.
No significant difference was found in CRP,IL-6,IL-8,TNF-α and PCT between the two groups ( >0.05),also no difference in APACHE Ⅱ,SIRS and Marshall scores ( >0.05). The gastric pH was remarkably higher in C+E group when compared to C group (5.02±1.61 vs.2.83±1.08, <0.001). There was no significant difference in the incidence of peptic ulcer and the rate of positive fecal occult blood between the two groups.
PPIs therapy did not show benefit on alleviating systemic inflammatory response and clinical scores in SAP patients,and didn't improve the prevention of peptic ulcer and gastrointestinal hemorrhage.
评估质子泵抑制剂(PPIs)治疗对重症急性胰腺炎(SAP)患者的影响。
2015年10月至2016年10月在本中心招募的45例SAP患者,随机分为两组:常规组(C组,n = 21)和常规+埃索美拉唑组(C+E组,n = 24)。C+E组静脉注射埃索美拉唑40 mg/d,持续1周,而C组仅接受基础治疗。在第1天(基线)和第7天通过酶联免疫吸附测定法检测血清C反应蛋白(CRP)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)和降钙素原(PCT)。在第1天(基线)、第3天和第7天获得急性生理与慢性健康状况评分Ⅱ(APACHEⅡ)、全身炎症反应综合征评分(SIRS)和改良马歇尔评分系统(Marshall)。在第7天通过内镜检查检测上消化道表现(消化性溃疡)和胃pH值。在第7天进行粪便潜血试验。
两组之间在CRP、IL-6、IL-8、TNF-α和PCT方面未发现显著差异(P>0.05),在APACHEⅡ、SIRS和Marshall评分方面也无差异(P>0.05)。与C组相比,C+E组的胃pH值明显更高(5.02±1.61对2.83±1.08,P<0.001)。两组之间消化性溃疡的发生率和粪便潜血阳性率无显著差异。
PPIs治疗在减轻SAP患者的全身炎症反应和临床评分方面未显示出益处,也未改善消化性溃疡和胃肠道出血的预防。